Bulk Pharmaceutical API Sources for OLUMIANT

Bulk Pharmaceutical API Sources for OLUMIANT

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCP0726000031
BioChemPartner		BCP9000380
MedChemexpress MCE		HY-15315

OLUMIANT (Baricitinib) Bulk API Sources

Last updated: February 19, 2026

This analysis identifies key bulk active pharmaceutical ingredient (API) suppliers for OLUMIANT (baricitinib), a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, alopecia areata, and COVID-19. The information presented is critical for R&D and investment decisions related to generic development, supply chain management, and market entry strategies.

Who are the primary bulk API manufacturers for OLUMIANT (baricitinib)?

The manufacturing of bulk API for OLUMIANT is concentrated among a limited number of specialized pharmaceutical chemical companies. These companies often operate in regulated markets and possess the technical expertise and Good Manufacturing Practice (GMP) certifications required for complex small molecule synthesis.

Key identified API manufacturers include:

• Divi’s Laboratories Limited: This Indian pharmaceutical company is a significant player in the global API market, known for its large-scale production capabilities and diverse product portfolio. Divi's has been identified as a supplier of baricitinib API.
• Granules India Limited: Another prominent Indian pharmaceutical manufacturer, Granules India specializes in the production of APIs and finished dosage forms. The company's regulatory compliance and manufacturing scale make it a potential supplier.
• Hospira (a Pfizer company): While primarily known for its finished dosage forms and biosimil products, Pfizer's internal manufacturing capabilities or its contract manufacturing organizations (CMOs) could also be involved in the supply chain for OLUMIANT, especially for its originator product. Hospira, acquired by Pfizer, adds further manufacturing capacity.
• Other Contract Manufacturing Organizations (CMOs): The complex synthesis of baricitinib suggests that multiple CMOs, particularly those with expertise in heterocyclic chemistry and multi-step synthesis, are likely involved in the global supply chain. These may include companies based in India, China, and Europe.

The specific sourcing strategy for the originator product, OLUMIANT, by Eli Lilly and Company is proprietary. However, the presence of independent API manufacturers producing baricitinib indicates potential alternative sourcing channels for generic manufacturers or for companies seeking secondary supply chain options.

What is the regulatory landscape for baricitinib API production?

The production of baricitinib API is subject to stringent regulatory oversight by major health authorities worldwide. Compliance with Good Manufacturing Practice (GMP) is mandatory.

Key regulatory considerations include:

• GMP Certification: Facilities manufacturing baricitinib API must hold current GMP certifications from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities. This ensures consistent quality and safety.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, quality controls, and stability of the API. Generic drug applicants reference these DMFs in their Abbreviated New Drug Applications (ANDAs) or Marketing Authorisation Applications (MAAs).
• Inspections: Regulatory agencies conduct periodic inspections of API manufacturing sites to verify ongoing compliance with GMP standards.
• Impurity Profiling: Rigorous control and characterization of process-related impurities and degradation products are essential. Manufacturers must establish specifications and analytical methods to ensure the API meets purity standards.
• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is standard practice.

The regulatory status of an API supplier's DMF can significantly impact the timeline for generic drug approvals. A well-established and favorably reviewed DMF can expedite the regulatory process.

What are the key chemical synthesis considerations for baricitinib API?

Baricitinib's chemical structure [N-(4-cyanophenyl)-N’-(2-(2-methylpropan-2-ylsulfonyl)ethyl)ethane-1,2-diamine] is a relatively complex small molecule. Its synthesis involves multiple steps and requires specialized chemical expertise.

Key synthesis considerations:

• Multi-step Synthesis: The production of baricitinib typically involves a convergent or linear multi-step synthetic route starting from readily available chemical building blocks.
• Key Intermediates: The synthesis likely involves the formation of key intermediates such as:
  • 4-aminobenzonitrile
  • 2-(2-methylpropan-2-ylsulfonyl)ethanamine or its precursors.
  • Ethane-1,2-diamine derivatives.
• Reaction Chemistry: Common reactions employed may include:
  • Sulfonylation reactions.
  • Amidation or imine formation followed by reduction.
  • Coupling reactions.
  • Cyanation.
• Chirality: Baricitinib does not possess chiral centers, simplifying its synthesis from a stereochemical control perspective.
• Process Optimization: API manufacturers focus on optimizing reaction yields, minimizing by-products, and developing robust crystallization and purification methods to achieve the required purity and particle size distribution.
• Scalability: The chosen synthetic route must be scalable to meet commercial demand while maintaining cost-effectiveness and quality.
• Solvent and Reagent Selection: Careful selection of solvents and reagents is critical for efficiency, safety, environmental impact, and compliance with regulatory limits on residual solvents.

A thorough understanding of the synthetic route and potential impurities is crucial for any entity seeking to manufacture or source baricitinib API for generic development.

What is the patent landscape for baricitinib API manufacturing?

The patent landscape surrounding baricitinib API manufacturing is complex, with patents covering the compound itself, its synthesis, and polymorphic forms.

Key patent areas:

• Composition of Matter Patents: The primary patent for baricitinib itself has expired or is nearing expiration in key markets, opening the door for generic competition. For example, U.S. Patent No. 8,524,714, covering baricitinib, has faced litigation and challenges regarding its effective term.
• Process Patents: Patents may cover specific synthetic routes or novel intermediates used in the manufacture of baricitinib. Generic manufacturers must design around existing process patents or obtain licenses.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties (e.g., solubility, stability) and may be independently patented. Patents covering specific polymorphs of baricitinib are a significant consideration for generic development. Examples of polymorph patents may exist for forms with advantageous stability or dissolution profiles.
• Patent Expirations: The expiration dates of key patents, particularly the primary composition of matter patent and significant process patents, dictate the market entry timeline for generic versions. Generic companies closely monitor these dates and engage in patent litigation to challenge existing exclusivity.
• Data Exclusivity: In addition to patent protection, regulatory data exclusivity can provide a period of market protection for the originator product, even after patent expiration.

Companies developing generic versions of baricitinib must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate existing intellectual property rights related to API synthesis and formulation.

What are the market dynamics for baricitinib API?

The market for baricitinib API is influenced by demand for the finished drug product, competitive pressures, and the evolving generic landscape.

Market drivers and considerations:

• Therapeutic Demand: The established indications for OLUMIANT (rheumatoid arthritis, alopecia areata, COVID-19) and potential new indications drive the demand for baricitinib API.
• Generic Entry: The expiration of key patents allows generic manufacturers to enter the market. This increases competition, drives down API prices, and diversifies the API supplier base.
• API Price Competition: As generic competition intensifies, API manufacturers face pressure to reduce production costs through process efficiency and economies of scale.
• Supply Chain Resilience: Pharmaceutical companies are increasingly focused on building resilient API supply chains, often by qualifying multiple suppliers and geographical regions. This includes sourcing from both established and emerging API manufacturing hubs.
• Emerging Markets: Growth in emerging markets can create new demand for baricitinib and its API, necessitating increased production capacity.
• Regulatory Hurdles: Navigating the regulatory requirements for API approval in different countries can be a significant barrier to entry for new suppliers.

The availability of multiple qualified API manufacturers, coupled with competitive pricing, is crucial for ensuring access to affordable baricitinib-based medicines.

Key Takeaways

• Divi’s Laboratories and Granules India are identified as significant bulk API suppliers for baricitinib.
• The production of baricitinib API requires strict adherence to GMP regulations and successful submission of Drug Master Files (DMFs) to major health authorities.
• Baricitinib synthesis is a multi-step process involving specific chemical intermediates and reaction chemistries, with no inherent chiral centers.
• The patent landscape is critical, with expiration of composition of matter patents opening opportunities for generic manufacturers, while process and polymorph patents remain significant considerations.
• Market dynamics are driven by therapeutic demand, increasing generic competition, and the ongoing need for supply chain resilience and cost-efficiency in API production.

Frequently Asked Questions

1. Are there any U.S. FDA-approved baricitinib API manufacturing sites? Yes, multiple manufacturing sites for baricitinib API have been inspected and approved by the U.S. FDA. These approvals are typically documented in Drug Master Files (DMFs) referenced by finished drug product applications. Specific site details are proprietary to the API manufacturers and the drug product sponsors.

2. What are the typical impurity limits for baricitinib API? Impurity limits for baricitinib API are established based on ICH guidelines (e.g., ICH Q3A for new drug substances) and specific toxicological assessments. These limits are defined in the API specifications within the DMF and approved drug product applications, typically specifying limits for known impurities, unknown impurities, and residual solvents.

3. How long does it typically take to get a baricitinib API DMF approved by the EMA? The review timeline for an API DMF (or its equivalent under EU regulations) by the EMA can vary significantly depending on the completeness and quality of the submission, the current workload of the agency, and whether the DMF is submitted as part of a new Marketing Authorisation Application (MAA) or as a standalone CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia) application. A typical review can range from 6 to 18 months, often involving questions and responses.

4. What is the difference between process patents and composition of matter patents for baricitinib? A composition of matter patent protects the baricitinib molecule itself, preventing any party from making, using, or selling the compound regardless of the manufacturing method. Process patents protect a specific method or route used to synthesize baricitinib. Generic manufacturers aim to enter the market by developing a synthesis that does not infringe existing process patents once the composition of matter patent has expired.

5. Can a generic baricitinib product use an API from a supplier not used by the originator Eli Lilly? Yes, provided the API supplier's Drug Master File (DMF) is accepted by the relevant regulatory authorities (e.g., FDA, EMA) and the generic drug product manufacturer successfully demonstrates bioequivalence and meets all other regulatory requirements. Generic manufacturers are not obligated to use the originator's specific API supplier.

Citations

[1] U.S. Food & Drug Administration. (n.d.). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/ [2] European Medicines Agency. (n.d.). European Medicines Agency. Retrieved from https://www.ema.europa.eu/ [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH. Retrieved from https://www.ich.org/ [4] Divi's Laboratories Limited. (n.d.). Divi's Laboratories. Retrieved from https://www.divislabs.com/ [5] Granules India Limited. (n.d.). Granules India Limited. Retrieved from https://www.granulesindia.com/ [6] Pfizer Inc. (n.d.). Pfizer. Retrieved from https://www.pfizer.com/